Lawyers Karina Tschon

Karina Tschon

Karina Tschon

Managing Associate
MLaw, Attorney at Law

vCard

Location

Contact

Direct phone: +41 58 658 14 39
karina.tschon@walderwyss.com

Curriculum Vitae

Areas of activity: Corporate / M&A Healthcare & Life Sciences Start-ups & Venture Capital

Karina Tschon works as an Attorney at Law at Walder Wyss. She advises clients on matters of commercial and corporate law.

Born in 1990, Karina Tschon studied at the University of Basel (BLaw 2014, MLaw 2016). Prior to joining Walder Wyss as an Attorney at Law, she worked as a trainee lawyer at the Civil District Court Basel-Landschaft East, the Criminal Court of Basel-Stadt, in a law firm in Basel and in the legal department of a pharmaceutical company in Basel. Karina Tschon was admitted to the bar in 2019 in the canton of Basel-Stadt.

Karina Tschon's professional languages are German and English.

SixPeaks Bio AG debuts with USD 110 million in Funding

Promotions at Walder Wyss

Nouscom Raises €67.5m ($72m) in Oversubscribed Series C Financing Round

15 November 2023

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

15 October 2023

Pierre Fabre Laboratories acquires Vertical Bio AG

13 September 2023

Alentis Therapeutics Closes USD 105m Series C Funding

Group of investors acquires iPet.ch GmbH

9 February 2023

BC Platforms Announces USD 20 Million Growth Financing led by Jolt Capital

9 November 2022

Versant Ventures launches Vector BioPharma with USD 30m Series A

ImmunOs Therapeutics Raises USD 74 Million Series B Financing Round

Astorg acquires CordenPharma from ICIG

Engimmune Therapeutics raises CHF 15.5m in Seed Financing

Versant Ventures launches Cimeio Therapeutics with USD 50m Series A

kooky secures financing in the amount of EUR 6 million

Memo Therapeutics Closes Series B Financing at CHF 37m Following Oversubscribed CHF 23m Extension

15 February 2022

Alloy Therapeutics acquires deepCDR Biologics

8 December 2021

GlycoEra CHF 45m Series A Financing

7 November 2021

Perconex Holding GmbH acquires Flex Suisse AG

31 October 2021

Polyphor and EnBiotix sign merger agreement and agreement on sale of Murapavadin

1 September 2021

Alentis Therapeutics raises USD 67m in Series B Financing

proLogistik Holding GmbH acquires XELOG AG

Calibre Scientific, Inc. acquires HUBERLAB.AG

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion

9 December 2020

Noema Pharma CHF 54m Series A Financing

2 December 2020

Synendos Therapeutics CHF 20m Series A Financing

11 November 2020

VectivBio USD 110m Crossover Financing

15 October 2020

Monte Rosa Therapeutics USD 96 million Series B Financing

28 September 2020

BioVersys CHF 19 mio. Series B Financing Round

2 September 2020

Versant Ventures launches Matterhorn Biosciences

Versant Ventures launches Bright Peak Therapeutics

Walder Wyss advises BC Platforms on $15 million Series C Financing and on a Partnership with IQVIA to Extend Data Analytics in Genomics

17 December 2019

Other lawyers

Technically necessary cookies

Essential technical cookies are necessary for the flawless functioning of our website and cannot be disabled.
Cookies for statistics

Analytical cookies enable us to count visits and traffic sources, allowing us to measure and enhance the performance of our website. They assist us in answering questions such as which pages are the most popular, which are the least used, and how visitors navigate the website. All information collected by these cookies is aggregated and therefore anonymous.
Marketing cookies may be set by our advertising partners on our website. These companies can use them to create a profile of your interests and display relevant advertisements on other websites. They operate by uniquely identifying your browser and device. By activating these cookies, you acknowledge and consent to the information collected by such cookies being sent to providers outside of Switzerland and the EU, including countries with (from the perspective of Swiss data protection law) inadequate data protection (e.g., the United States, Singapore, and Taiwan). You also acknowledge that data transmitted abroad is no longer protected by Swiss law, and foreign laws as well as regulatory orders may require the disclosure of this data to authorities and other third parties.

Marketing cookies may be set by our advertising partners on our website. These companies can use them to create a profile of your interests and display relevant advertisements on other websites. They operate by uniquely identifying your browser and device. By activating these cookies, you acknowledge and consent to the information collected by such cookies being sent to providers outside of Switzerland and the EU, including countries with (from the perspective of Swiss data protection law) inadequate data protection (e.g., the United States, Singapore, and Taiwan). You also acknowledge that data transmitted abroad is no longer protected by Swiss law, and foreign laws as well as regulatory orders may require the disclosure of this data to authorities and other third parties.